{"title": "AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2", "doi": "10.1101/2020.03.03.972133", "citation_id": "2020.03.03.972133v1", "date": "2020-03-08", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.03.03.972133", "abstract": "<p>The focused drug repurposing of known approved drugs (such as lopinavir/ritonavir) has been reported failed for curing SARS-CoV-2 infected patients. It is urgent to generate new chemical entities against this virus. As a key enzyme in the life-cycle of coronavirus, the 3C-like main protease (3CLpro or Mpro) is the most attractive for antiviral drug design. Based on a recently solved structure (PDB ID: 6LU7), we developed a novel advanced deep Q-learning network with the fragment-based drug design (ADQN-FBDD) for generating potential lead compounds targeting SARS-CoV-2 3CLpro. We obtained a series of derivatives from those lead compounds by our structure-based optimization policy (SBOP). All the 47 lead compounds directly from our AI-model and related derivatives based on SBOP are accessible in our molecular library at https://github.com/tbwxmu/2019-nCov. These compounds can be used as potential candidates for researchers in their development of drugs against SARS-CoV-2.</p>", "twitter_description": "The focused drug repurposing of known approved drugs (such as lopinavir/ritonavir) has been reported failed for curing SARS-CoV-2 infected patients. It is urgent to generate new chemical entities against this virus. As a key enzyme in the life-cycle of coronavirus, the 3C-like main protease (3CLpro or Mpro) is the most attractive for antiviral drug design. Based on a recently solved structure (PDB ID: 6LU7), we developed a novel advanced deep Q-learning network with the fragment-based drug design (ADQN-FBDD) for generating potential lead compounds targeting SARS-CoV-2 3CLpro. We obtained a series of derivatives from those lead compounds by our structure-based optimization policy (SBOP). All the 47 lead compounds directly from our AI-model and related derivatives based on SBOP are accessible in our molecular library at <https://github.com/tbwxmu/2019-nCov>. These compounds can be used as potential candidates for researchers in their development of drugs against SARS-CoV-2.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.03.972133v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.03.03.972133v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.03.972133v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/08/2020.03.03.972133.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.03.03.972133v1", "access_rights": "restricted", "authors": ["Bowen Tang", "Fengming He", "Dongpeng Liu", "Meijuan Fang", "Zhen Wu", "Dong Xu"]}